0000000000550161
AUTHOR
Pablo Hueso
Effect of simulated gastrointestinal digestion on sialic acid and gangliosides present in human milk and infant formulas.
The effects of simulated gastrointestinal digestion upon sialic acid and gangliosides in infant and follow-on formulas and human milk, as well as their bioaccessibility, have been evaluated. The gastric stage is the step that causes a greater decrease in sialic acid and ganglioside contents. The intestinal stage only decreases the total and individual contents of gangliosides. After gastrointestinal digestion, neither sialic acid nor gangliosides were found in the nonbioaccessible fraction. The highest bioaccessibility (100 × content in soluble fraction after gastrointestinal digestion/total content) of sialic acid is found in human milk (87%), followed by infant formula (77%) and follow-on…
Sialic acid (N-acetyl and N-glycolylneuraminic acid) and ganglioside in whey protein concentrates and infant formulae
Abstract Sialic acid and gangliosides content and profiles were analyzed in infant formulae, whey protein concentrates and human milk. In infant formulae, N-acetylneuraminic (Neu5Ac) and N-glycolylneuraminic (Neu5Gc) acid ranged from 147.6–199.7 to 3.3–8.3 mg L −1 , in whey protein concentrate from 1.6–2.4 g 100 g −1 to 2.8–20.2 mg 100 g −1 and in human milk from 299.9 to 2.1 mg L −1 . Gangliosides ranged from 0.25 to 2.29 mg lipid-bound sialic acid L −1 in reconstituted infant formula, the main gangliosides being GD 3 (73.3–55.5%), GM 3 (3.5–36.6%) and GT 3 (1.4–14.1%) and O-acetyl-GD 3 (5.3–18.9%). In whey protein concentrates, 0.7–55.6 mg lipid-bound sialic acid 100 g −1 were found with …